Role of telomere shortening in anticipation of inflammatory bowel disease

Table 1 Patient included in genetic anticipation analysis- characteristics and disease severity

ID	Member	IBD	Tobacco	AOD	NOD2	Extent	Behavior	Medications	Surgery
1-01	Mother	CD	None	21	+	Ileum, colon	B2	Steroids 5-ASA	Yes
1-02	Proband/F	CD	Former	9	+	Ileum, jejunum, colon	B3p	Steroids 5-ASA	No
1-05	Sister	CD	None	14	+	Ileum, colon	B2	Steroids 5-ASA thiopurine	No
1-07	Grandmother	CD	Passive	42	+	Ileum, colon	B2	5-ASA	Yes
2-01	Father	IBD-U	Active	21	_	Left colon	NA	5-ASA, thiopurine	Yes
2-02	Proband/F	UC	Active	4	_	Left colon	NA	Steroids 5-ASA, thiopurine	Yes
2-03	Grandfather	UC	Former	63	_	Left colon	NA	Steroids 5-ASA	Yes
3-01	Mother	UC	None	40	_	Left colon	NA	Steroids 5-ASA	Yes
3-03	Proband/M	UC	None	19	_	Left colon	NA	Steroids	No
3-04	Uncle	UC	Active	41	_	Left colon	NA	Steroids 5-ASA	No
3-05	Grandfather	IBD-U	Former	56	_	Pancolitis	NA	Steroids	No

There was no available TL data for the member 3-05. B2: Stricturing disease; and B3: Penetrating disease, as per Montreal Classification; Steroids: Refers to prednisone; Surgery: Refers to total colectomy for ulcerative colitis and segmental bowel resection for Crohn’s disease. F: Female; M: Male; CD: Crohn’s disease; UC: Ulcerative colitis; IBD-U: Indeterminate colitis; 5-ASA: 5–aminosalicilates; AOD: Age at diagnosis; TL: Telomere length; NOD2: NOD2 gene; NA: Not applicable.